MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI)

Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (88.41% upside)

Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Show:
DateFirmActionRatingPrice TargetActions
7/14/2015William BlairReiterated RatingOutperform$5.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015William BlairReiterated RatingOutperform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015Needham & Company LLCLower Price TargetBuy$14.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2014William BlairSet Price TargetBuy$8.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Needham & Company LLCSet Price TargetBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2014Stifel NicolausLower Price TargetBuy$21.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2014RBC CapitalDowngradeOutperform -> Sector Perform$19.00 -> $4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2014Needham & Company LLCDowngradeStrong-Buy -> Buy$30.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2014CRT CapitalInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2013Stifel NicolausLower Price TargetBuy$26.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2013Needham & Company LLCUpgradeBuy -> Strong-Buy$20.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/9/2013Stifel NicolausLower Price TargetBuy$30.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/3/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha